Ali Khaki

Hematology | Oncology
875 Blake Wilbur Dr
Palo Alto, CA 94304

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 80 publications

Association of Early Same-Day Posttherapy Whole-Body SPECT/CT Using Visual RECIP 1.0 with Overall Survival During [177Lu]Lu-PSMA-617 Therapy for Metastatic Castration-Resistant Prostate Cancer.

Association of Early Same-Day Posttherapy Whole-Body SPECT/CT Using Visual RECIP 1.0 with Overall Survival During [177Lu]Lu-PSMA-617 Therapy for Metastatic Castration-Resistant Prostate Cancer.

Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: April 01, 2026

Baseline Hematological Parameters and Outcomes in Patients With Prostate Cancer Treated With Lu-177 PSMA Radioligand Therapy (RLT): A Multicenter Real-World Analysis.

Baseline Hematological Parameters and Outcomes in Patients With Prostate Cancer Treated With Lu-177 PSMA Radioligand Therapy (RLT): A Multicenter Real-World Analysis.

Journal: Clinical genitourinary cancer
Published: December 17, 2025

Real-World Outcomes of Patients With Baseline Neuropathy and/or Diabetes Mellitus Receiving Enfortumab Vedotin-Based Regimens for Advanced Urothelial Carcinoma in the UNITE Database.

Real-World Outcomes of Patients With Baseline Neuropathy and/or Diabetes Mellitus Receiving Enfortumab Vedotin-Based Regimens for Advanced Urothelial Carcinoma in the UNITE Database.

Journal: Clinical genitourinary cancer
Published: December 02, 2025

Molecularly Targeted Cancer Medications and Kidney Health.

Molecularly Targeted Cancer Medications and Kidney Health.

Journal: JAMA network open
Published: November 06, 2025

Genomic Landscape and Outcomes of Renal Cell Carcinoma With Metastases to the Pancreas.

Genomic Landscape and Outcomes of Renal Cell Carcinoma With Metastases to the Pancreas.

Journal: JCO precision oncology
Published: November 06, 2025

Complete response in metastatic renal cell carcinoma: impact of a persistent primary lesion.

Complete response in metastatic renal cell carcinoma: impact of a persistent primary lesion.

Journal: BJU international
Published: November 04, 2025

Treatment Sequencing in Advanced Urothelial Cancer.

Treatment Sequencing in Advanced Urothelial Cancer.

Journal: Drugs
Published: September 02, 2025

Preferred Treatment Sequencing for Metastatic Urothelial Carcinoma (mUC) in the Era of Perioperative and First-Line (1L) Checkpoint Inhibitor: Results From a National Survey of Genitourinary Oncologists.

Preferred Treatment Sequencing for Metastatic Urothelial Carcinoma (mUC) in the Era of Perioperative and First-Line (1L) Checkpoint Inhibitor: Results From a National Survey of Genitourinary Oncologists.

Journal: Clinical genitourinary cancer
Published: July 16, 2025

Cost-Effectiveness of Trimodal Therapy and Radical Cystectomy for Muscle-Invasive Bladder Cancer.

Cost-Effectiveness of Trimodal Therapy and Radical Cystectomy for Muscle-Invasive Bladder Cancer.

Journal: JAMA network open
Published: June 23, 2025

Efficacy of erdafitinib before or after enfortumab vedotin in FGFR3-altered advanced urothelial cancer: analysis of the UNITE collaborative study.

Efficacy of erdafitinib before or after enfortumab vedotin in FGFR3-altered advanced urothelial cancer: analysis of the UNITE collaborative study.

Journal: The oncologist
Published: June 09, 2025

Efficacy of sacituzumab govitecan after enfortumab vedotin in advanced urothelial carcinoma: Analysis of the UNITE study.

Efficacy of sacituzumab govitecan after enfortumab vedotin in advanced urothelial carcinoma: Analysis of the UNITE study.

Journal: Urologic oncology
Published: May 19, 2025

Outcomes with Enfortumab Vedotin in Patients with Histologic Subtypes of Advanced Urothelial Carcinoma: Analysis of the UNITE Study.

Outcomes with Enfortumab Vedotin in Patients with Histologic Subtypes of Advanced Urothelial Carcinoma: Analysis of the UNITE Study.

Journal: European urology
Published: May 07, 2025
Showing 1-12 of 80

Last Updated: 09/26/2026